Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Genentech Was Too Slow In Trying To Halt Amgen's Herceptin Biosimilar Launch

Jul 26 2019

• By Brenda Sandburg

Lady justice on top of a snail - Illustration — Genentech delayed seeking a preliminary injunction to halt Hercpetin biosimilar launch.

Related Content

How Risky Is Amgen's At-Risk Launch Of Herceptin, Avastin Biosimilars?

Jul 22 2019

Related Companies

Genentech, Inc.

Amgen, Inc.

Roche Holding AG

Viatris Inc.

Celltrion, Inc.

Pfizer Inc.

Teva Pharmaceutical Industries Ltd.

Samsung Bioepis Co., Ltd.

Additional Topics

United States Biosimilars Intellectual Property Legal Issues Policy Cancer BioPharmaceutical

More from Biosimilars

More from Biosimilars & Generics

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.